Blockade of the RAAS and Ang II with angiotensin-converting enzyme inhibitors andAng II receptor blockers (either combined or alone), have shown to be effectivein reducing proteinuria and delaying the progression of DKD by theirhemodynamic/anti-hypertensive, anti-inflammatory and antifibrotic effects, andhence could be used to improve the prognosis of DKD patients.58 The gene discussed is ACE; the disease is diabetic kidney disease.